

Activity Outline
Topics in Public Health: Diagnosis & Management of Nonalcoholic Fatty Liver Disease in the Pediatric Patient
June 3, 2022
Webinar

Activity Coordinators:

Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov), Jessica Voqui (jessica.voqui@fda.hhs.gov)

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

Nonalcoholic fatty liver disease (NAFLD) is defined as excessive fat deposition in the liver after metabolic, infectious, genetic, dietary, alcohol consumption and medications have been ruled out as a possible cause; essentially, it is a diagnosis of exclusion. Healthcare providers are inconsistently diagnosing and managing Nonalcoholic Fatty Liver Disease in children. This is most likely due to the lack of recommendations regarding screening in this age group and the limited options for treatment. This presentation will give an overview of this frequently missed comorbidity of childhood obesity, discuss recent guidelines and demonstrate how these guidelines can be put into practice.

This activity may reference off-label use of FDA-approved products.

References

- Suri Anandini, Song Eric, van Nispen Johan, Voigt Marcus, Armstrong, Austin, Murali Vidul, Jain Ajay. Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease. *Clinical Therapeutics* 2021; 43:438-454.
- Shah Jay, Okubote Toluwalase, Alkhouri Naim. Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. *Gastroenterology & Hepatology* 2018; 14:407-414.

Series Objectives

- Increase awareness of current topics in public health
- Help improve patient/public health outcomes
- Help participants modify their practice within their job or deployments

Learning Objectives After completion of this activity, the participant will be able to:

- Recall the multiple risk factors associated with nonalcoholic fatty liver disease thus improving their screening process during preventive care encounters.
- Once risk factors for nonalcoholic fatty liver are identified, identify labs and diagnostic tests to obtain and how to analyze the results.
- Select the best next steps in management of children with nonalcoholic fatty liver disease.

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health..

Agenda

Lecture 1 June 3, 2022

TIME	TOPIC	SPEAKER
2:00 - 3:00 PM EDT	Diagnosis & Management of Nonalcoholic Fatty Liver Disease in the Pediatric Patient	Leticia Hardy, MD

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-22-026-L04-P, and ACPE Universal Activity Number JA0002895-0000-22-026-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- Hardy, Leticia, MD, Pediatrician, Team Health - *nothing to disclose*

Planning Committee

- BIRCH-SMITH, POSTELLE, PharmD - *nothing to disclose*
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - *nothing to disclose*
- Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - *nothing to disclose*
- La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - *nothing to disclose*
- Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - *nothing to disclose*
- McClain, Rena, PharmD, CMS - *nothing to disclose*
- Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - *nothing to disclose*
- Radden, Erica - *nothing to disclose*

CE Consultation and Accreditation Team

- Catherine Harrison, CE Consultant, FDA/CDER/OEP/DLOD - *nothing to disclose*
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - *nothing to disclose*

All of the relevant financial relationships listed for these individuals have been mitigated.

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.